Individual Services or Full Service Global CRO Capabilities.
Novel Approaches to Save Sponsors Time and Money.
Adherence to Sponsor Timelines.
Lowest Turnover Rate in the Industry, <5% for CRAs, CTAs and Project Managers.
The Karma Oncology team is experienced in managing oncology trials in many different tumour types and using different therapeutic approaches.
The founder of the company, Dr Williams, has 30 years clinical research experience and has worked in both the pharmaceutical and CRO industries during her career. She has a BSc (Hons) in biology and P...
Our CPMs have a wealth of experience managing oncology clinical trials. Educated to degree/higher degree level or with nursing/midwifery backgrounds. Excellent communication and organisational skills....
CRAs are all ‘career’ CRAs, ie they have committed and are not looking for a step up the corporate ladder. CRAs, all mature, come from a variety of backgrounds including oncology research ...
Our CTAs are all educated to degree level....
Karma Oncology will attend a number of events. If you wish to set up a meeting with us to hear more about our unique organisation and how our expertise in delivering oncology clinical trials can support your oncology portfolio, please contact;
BioTech Showcase 7-9 Jan. 2019, San FranciscoBIO Europe Spring: 25-27 Mar. 2019, ViennaAACR Annual Meeting: 30 Mar. – 3 Apr. 2019, AtlantaWorld Advanced Therapies & Regenerative Medicine: 15-17 May 2019, London
We are pleased to announce that Karma Oncology’s very own Dr Karen J. Williams will be speaking at the Clinical Operations in Oncology Trials Conference in Munich, Nov 14-15 2018.
Fantastic achievement and we wish her the best of luck!
To arrange a meeting and learn more about our unique, oncology specialized clinical research company, and how we can support your oncology portfolio please contact: firstname.lastname@example.org
Our skilled team design clinical development plans & clinical study protocols, perform clinical trial start-up & execution and reporting. With a flexible, competitive approach in all aspects of our business, we are committed to delivering successful, high quality trials within sponsor timelines.
Don’t forget to follow Karma Oncology on all social media platforms to stay up to date and receive news.
Karma Oncology was awarded the French Research Tax Credit approval in 2017. This approval will help our existing and future clients in France to benefit from this R&D tax credit. Since Karma Oncology is listed as an “approved organization”, the French ministry will allow for significant refunds by any French R&D company on their spending on Karma Oncology services. The research tax credit is either deducted from annual corporate tax or reimbursed and is calculated based on the amount (“volume”) of R&D expenditure by the company in France.